Tvardi Reports Improved Q1 Loss, Positive IPF Data, Cash Runway into Q4 2026
TVRD sits 45% above its 52-week low of $2.75 on elevated volume (2.2× avg).
Summary
Tvardi Therapeutics reported a net loss of $6.8 million for Q1 2026, an improvement from $9.6 million in the prior year, with cash and equivalents at $25.0 million. The company anticipates its cash runway will fund operations into Q4 2026. This financial update follows a recent S-3 filing for a $200 million mixed shelf offering and a $12.5 million At-The-Market program, and a prior 10-K warning about its ability to continue as a going concern. Additionally, Tvardi provided positive Phase 2 data for TTI-101 in IPF, showing a 9.4% baseline-weighted reduction in fibrosis score compared to 2.4% for placebo, and a 4.5-fold greater decline in IL-6. Traders will monitor the capital raise and upcoming topline data for TTI-109 in June and TTI-101 in HCC in 2H 2026.
At the time of this announcement, TVRD was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.5M. The 52-week trading range was $2.75 to $43.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.